Duality Biotherapeutics, Inc.(HK:9606)
HK$108.70+0.30 (+0.28%)
HK:9606
Duality Biotherapeutics, Inc. financials statements
HK$108.70
At close:+0.30 (+0.28%)
Want to see HK:9606 full AI Analyst Report?
Duality Biotherapeutics, Inc. (9606) Ratios
5 Followers
Duality Biotherapeutics, Inc. Ratios
HK:9606's free cash flow for Q2 2026 was ¥0.00. For the 2026 fiscal year, HK:9606's free cash flow was increased by ¥0.00 and operating cash flow was ¥0.00. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 |
|---|---|---|---|---|
| Liquidity Ratios | ||||
| Current Ratio | 3.61 | 0.49 | 0.52 | 0.33 |
| Quick Ratio | 3.61 | 0.49 | 0.52 | 0.33 |
| Cash Ratio | 1.26 | 0.31 | 0.44 | 0.31 |
| Solvency Ratio | -1.71 | -0.25 | -0.13 | -0.31 |
| Operating Cash Flow Ratio | 0.18 | 0.07 | 0.32 | -0.24 |
| Short-Term Operating Cash Flow Coverage | 1.38 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | ¥ 2.33B | ¥ -2.20B | ¥ -1.29B | ¥ -827.97M |
| Leverage Ratios | ||||
| Debt-to-Assets Ratio | 0.04 | 0.00 | 0.00 | 0.01 |
| Debt-to-Equity Ratio | 0.06 | -0.00 | -0.00 | -0.01 |
| Debt-to-Capital Ratio | 0.06 | -0.00 | -0.00 | -0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.60 | -1.03 | -1.33 | -0.60 |
| Debt Service Coverage Ratio | -17.68 | -4169.26 | -1874.13 | -5136.27 |
| Interest Coverage Ratio | -353.16 | -755.97 | 4156.14 | -4914.44 |
| Debt to Market Cap | 0.01 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 2.32 | 0.07 | 0.07 | 0.06 |
| Net Debt to EBITDA | 0.47 | 1.20 | 5.71 | 0.96 |
| Profitability Margins | ||||
| Gross Profit Margin | 31.15% | 40.42% | 76.06% | 100.00% |
| EBIT Margin | -140.06% | -52.25% | -11.31% | -24188.44% |
| EBITDA Margin | -139.38% | -51.84% | -11.03% | -24076.25% |
| Operating Profit Margin | -23.08% | -9.74% | 43.74% | -23036.44% |
| Pretax Profit Margin | -140.13% | -52.26% | -11.32% | -24193.13% |
| Net Profit Margin | -140.13% | -54.11% | -20.01% | -24193.13% |
| Continuous Operations Profit Margin | -140.13% | -54.11% | -20.01% | -24193.13% |
| Net Income Per EBT | 100.00% | 103.54% | 176.77% | 100.00% |
| EBT Per EBIT | 607.23% | 536.82% | -25.88% | 105.02% |
| Return on Assets (ROA) | -64.90% | -50.25% | -23.84% | -83.47% |
| Return on Equity (ROE) | -104.12% | 51.95% | 31.81% | 50.33% |
| Return on Capital Employed (ROCE) | -14.65% | 10.61% | -73.62% | 48.05% |
| Return on Invested Capital (ROIC) | -13.93% | 10.63% | -73.82% | 48.22% |
| Return on Tangible Assets | -64.97% | -51.39% | -24.73% | -93.82% |
| Earnings Yield | -14.48% | -6.56% | -2.31% | -2.57% |
| Efficiency Ratios | ||||
| Receivables Turnover | 6.24 | 5.12 | 17.72 | 1.08 |
| Payables Turnover | 1.63 | 1.72 | 1.82 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 62.88 | 104.40 | 100.60 | 0.23 |
| Asset Turnover | 0.46 | 0.93 | 1.19 | 0.00 |
| Working Capital Turnover Ratio | 4.59 | -1.22 | -1.74 | 0.00 |
| Cash Conversion Cycle | -165.51 | -140.45 | -179.81 | 336.48 |
| Days of Sales Outstanding | 58.51 | 71.27 | 20.60 | 336.48 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 224.02 | 211.73 | 200.41 | 0.00 |
| Operating Cycle | 58.51 | 71.27 | 20.60 | 336.48 |
| Cash Flow Ratios | ||||
| Operating Cash Flow Per Share | 2.99 | 3.44 | 9.81 | -3.60 |
| Free Cash Flow Per Share | 2.78 | 3.06 | 9.38 | -3.87 |
| Dividend Paid and CapEx Coverage Ratio | 14.18 | 9.17 | 22.74 | -13.49 |
| Capital Expenditure Coverage Ratio | 14.18 | 9.17 | 22.74 | -13.49 |
| Operating Cash Flow Coverage Ratio | 1.30 | 54.03 | 153.50 | -64.20 |
| Operating Cash Flow to Sales Ratio | 0.11 | 0.15 | 0.46 | -187.17 |
| Free Cash Flow Yield | 1.04% | 1.59% | 5.05% | -2.14% |
| Valuation Ratios | ||||
| Price-to-Earnings (P/E) Ratio | -6.90 | -15.25 | -43.22 | -38.90 |
| Price-to-Sales (P/S) Ratio | 9.67 | 8.25 | 8.65 | 9410.04 |
| Price-to-Book (P/B) Ratio | 7.19 | -7.92 | -13.75 | -19.58 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 96.49 | 62.90 | 19.80 | -46.81 |
| Price-to-Operating Cash Flow Ratio | 89.69 | 56.04 | 18.93 | -50.28 |
| Price-to-Earnings Growth (PEG) Ratio | -0.03 | -0.08 | 5.74 | 0.00 |
| Enterprise Value Multiple | -6.47 | -14.72 | -72.69 | -38.12 |
| Enterprise Value | 16.27B | 14.81B | 14.32B | 14.68B |
| EV to EBITDA | -6.47 | -14.72 | -72.69 | -38.12 |
| EV to Sales | 9.02 | 7.63 | 8.02 | 9177.97 |
| EV to Free Cash Flow | 89.99 | 58.17 | 18.35 | -45.65 |
| EV to Operating Cash Flow | 83.64 | 51.83 | 17.55 | -49.04 |
| Tangible Book Value Per Share | 37.20 | -24.86 | -14.16 | -9.86 |
| Shareholders’ Equity Per Share | 37.26 | -24.31 | -13.51 | -9.25 |
| Tax and Other Ratios | ||||
| Effective Tax Rate | 0.00 | -0.04 | -0.77 | 0.00 |
| Revenue Per Share | 27.68 | 23.34 | 21.48 | 0.02 |
| Net Income Per Share | -38.79 | -12.63 | -4.30 | -4.65 |
| Tax Burden | 1.00 | 1.04 | 1.77 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.45 | 0.43 | 0.31 | 212.43 |
| SG&A to Revenue | 0.09 | 0.02 | 0.02 | 9.43 |
| Stock-Based Compensation to Revenue | 0.09 | 0.10 | 0.01 | 4.39 |
| Income Quality | -0.07 | -0.28 | -4.04 | 0.77 |
Currency in CNY
